Phase 1 trial results from a novel long acting NPY2-receptor agonist in partnership between Gubra A/S and Boehringer Ingelheim presented today at the European Congress on Obesity, ECO 2023
Prenumeration
Beskrivning
| Land | Danmark |
|---|---|
| Lista | Mid Cap Copenhagen |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
- BI 1820237 a novel long-acting neuropeptide Y receptor type 2 (NPY2) agonist, has been evaluated in a phase 1 clinical trial.
- Results to be presented today at the ECO 2023 congress in Dublin, Ireland.
- The trial showed no unexpected safety concerns, and positive effects on energy intake and gastric emptying.
- BI 1820237 originates from an ongoing collaboration between Boehringer Ingelheim and Gubra A/S.
Today, at the 30th European Congress on Obesity (ECO 2023) in Dublin, Ireland, Boehringer Ingelheim shares phase 1 results for BI 1820237, a long acting NPY2 receptor agonist drug candidate developed in collaboration with Gubra A/S.
The phase 1 trial (NCT04903509) was a placebo-controlled study consisting of 3 parts: Part 1: testing single increasing subcutaneous doses of the novel NPY2 receptor agonist, part 2: increasing the number of participants in the high dose group and part 3: exploring low-to-medium doses of the NPY2 receptor agonist in combination with low-dose liraglutide. Participants in the trial were healthy men with overweight/obesity. The results show no unexpected safety or tolerability concerns with single doses of BI 1820237 with and without liraglutide. Adverse events were primarily gastro-intestinal in nature and the frequency increased with increasing dose. Treatment with BI 1820237 decreased energy intake and delayed gastric emptying in healthy men with overweight/obesity, supporting further investigations of the drug candidate.
Niels Vrang, Chief Scientific Officer at Gubra A/S, expressed satisfaction with the results and the continued development of this peptide by Boehringer Ingelheim as a potential anti-obesity medication:
“We are excited to see data from the phase 1 trial presented by Boehringer Ingelheim at the annual European Congress on Obesity. Data are in line with observations in several animal models. We look forward to seeing how this NPY2-receptor agonist can be used in combination with approved obesity drugs, e.g. GLP-1 receptor agonists and other obesity drug candidates currently in development, to potentially improve therapy - better effect and/or a better tolerability profile for the benefit for people living with obesity. It will be exciting to follow this project as it moves forward.”